Retrospective review of Pneumocystis jirovecii pneumonia over two decades

J Travis1, E Hart, J Helm

  • 1Department of Infectious Diseases, The Monsall Unit, North Manchester General Hospital, Manchester, UK. jennytravis@doctors.org.uk

Insights

Mortality for ventilated Pneumocystis pneumonia (PJP) patients with HIV significantly decreased by 50% between 1986-1995 and 1997-2004. This improvement is attributed to better intensive care, not specific PJP treatments.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Pneumocystis pneumonia (PJP) is a severe opportunistic infection, particularly in individuals with Human Immunodeficiency Virus (HIV).
  • Previous audits indicated a 100% mortality rate for ventilated PJP patients between 1986-1995.

Purpose of the Study:

  • To compare PJP case notes from 1997-2004 with previous audit data (1986-1995).
  • To assess changes in PJP patient demographics, management, and outcomes, particularly for severe cases requiring ventilation.

Main Methods:

  • Retrospective case note review of PJP cases at North Manchester General Hospital (1997-2004).
  • Comparison with an earlier audit of PJP cases (1986-1995).
  • Analysis of patient demographics, HIV status, CD4 counts, viral load, and ventilation requirements.

Main Results:

  • 210 PJP cases diagnosed 1997-2004, with 64 severe cases. Median age 39 years.
  • 18 patients required intubation; 9 (50%) survived 30 days postextubation.
  • Significant reduction in mortality for ventilated severe PJP patients compared to the 1986-1995 cohort (100% mortality).

Conclusions:

  • Improved intensive care management of respiratory failure has led to a 50% reduction in mortality for ventilated severe PJP patients.
  • Ventilation for HIV-positive patients with PJP is no longer a universally fatal outcome.
  • Advances in critical care have significantly improved survival rates for severe PJP cases.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: